Biogen Shares Rise After Positive Litifilimab Phase 2 CLE Data Biogen reported a second positive Phase 2 litifilimab result at Week 16; data presented Mar 28, 2026 (source: Business Insider/GlobeNewswire).

Biogen Shares Rise After Positive Litifilimab Phase 2 CLE Data: Biogen reported a second positive Phase 2 litifilimab result at Week 16; data presented Mar 28, 2026 (source: Business Insider/GlobeNewswire). 👈 Read full analysis #Biogen #Litifilimab #Phase2ClinicalTrial #Pharmaceuticals #Healthcare

バイオジェン、リチフィリマブが皮膚ループスでFDAブレークスルー指定──BDCA2標的の第3相は2027年読出し予定 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研

バイオジェン、リチフィリマブが皮膚ループスでFDAブレークスルー指定──BDCA2標的の第3相は2027年読出し予定
Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for cutaneous lupus erythematosus

stellanews.life/technology/8...

#CutaneousLupus #CLE #Litifilimab #BIIB059 #BDCA2 #BreakthroughTherapy

Lupus Research Alliance Celebrates FDA's Breakthrough Designation for Litifilimab: A Significant Step in Treating Cutaneous Lupus Erythematosus The Lupus Research Alliance hails FDA's Breakthrough Therapy status for Litifilimab, aiming to fast-track treatment for Cutaneous Lupus Erythematosus, impacting many lives.

Lupus Research Alliance Celebrates FDA's Breakthrough Designation for Litifilimab: A Significant Step in Treating Cutaneous Lupus Erythematosus #USA #New_York #Lupus_Research_Alliance #FDA_Designation #Litifilimab